Acute intermittent porphyria (AIP) often presents with recurrent attacks of abdominal pain and vomiting. Many stimuli can precipitate attacks, including menstruation. CASE HISTORIES Patient 1
The ®rst patient, now aged 24, was originally diagnosed with AIP genetic trait at age 11, after family screening ( Figure 1 ). Recurrent attacks of abdominal pains and vomiting (occasionally with headaches and leg pains) began at age 13.
Over the years, she had multiple acute attacks of abdominal pain, averaging 10±20 hospital admissions per year. There was well-documented evidence of raised porphyrin precursors during acute attacks and normal levels in between attacks (for example, during an attack urinary porphobilinogen [PBG] 310 mmol/L [reference range 0±8.8] and aminolaevulinic acid [ALA] 275 mmol/L [0.8±34.3]). As well as occasional unpredictable attacks, she would regularly experience an acute attack one week before menstruation. Typically this led to hospital admission for intravenous¯uids, high carbohydrate intake and opioid analgesia; usually she stayed in hospital for 2 weeks per month. She required frequent pethidine or morphine, became depressed and required admission to the drug dependency unit for formal opioid withdrawal. She felt that her relationship with her 2-year-old son was seriously affected by the frequent hospital admissions.
In January 1996, after appropriate barrier contraceptive advice, she was started on nafarelin nasal spray 400 mg twice daily and referred for both dual emission X-ray absorption (DEXA) scan to measure baseline bone mineral density and gynaecological follow-up of her endometrium. She became amenorrhoeic and the attacks of AIP resolved.
In the 3 years she has been receiving nafarelin she has been admitted 12 times with abdominal pain, at least 6 of the admissions being preceded by non-use of her nafarelin spray (usually because of nasal irritation); on two further occasions, attacks resumed within weeks of the introduction of oestrogen. Oestrogen was used in an attempt to confer bone protection without precipitating an AIP attack, but even when the transdermal route (Estraderm TTS patch 50 mg twice weekly) was used to avoid hepatic ®rst-pass metabolism, acute AIP ensued. This left only 4 unaccounted attacks of AIP over the 3 years, compared with the 36 that would have been expected. She has been attack-free for eight months. She now awaits a repeat DEXA scan to assess any possible loss in bone mineral density.
Patient 2
The sister of patient 1, now aged 22, was originally diagnosed with AIP genetic trait at age 9. Attacks of abdominal pain began at age 11 years. These seemed less severe than her sister's and indeed she has only required hospital admission on 3 occasions. Again there was welldocumented evidence of raised porphyrin precursors during the attacks with normal levels between attacks (for example, during an attack urinary PBG 497 mmol/L). She too experienced perimenstrual exacerbations, with severe abdominal pains for 3 days before menstruation and 2 days subsequently. After appropriate contraceptive advice she was started on nafarelin spray 400 mg twice daily and was referred for DEXA and gynaecological follow-up. She became amenorrhoeic and is currently attack-free at eight months.
COMMENT
The acute porphyrias are hereditary disorders of haem biosynthesis, with clinically overt disease in about 1±2 per 100 000 of the population of Europe 1 . They lead to accumulations of the precursors of haemÐALA, PBG and porphyrinogens. Acute intermittent porphyria is an autosomal dominant inborn error of metabolism due to a defect in PBG deaminase. Most cases are silent and women are more likely to manifest acute attacks than men. 95% of cases are characterized by abdominal pain and vomiting, but psychiatric and neurological symptoms occur, with some attacks resulting in death. Alcohol, stress, starvation, infections, sex steroids (including the oral contraceptive pill) and many drugs that tend to increase ALA synthase activity can precipitate acute attacks.
Nafarelin, a decapeptide gonadotropin-releasing hormone (GnRH) agonist analogue, produces initial stimulation, and then with continued administration downregulation of the pituitary gonadotropin-releasing hormone receptors, reducing the release of luteinizing hormone and follicular stimulating hormone and in turn androgen and oestrogen production. Indications for use of GnRH analogues include endometriosis, infertility, anaemia secondary to ®broids and cancer of the breast and prostate. GnRH analogues have been used for prevention of cyclical attacks of AIP since 1984 2 , but therapy has usually been short-term. Patient 1 has now been on treatment for thirty-six months and preservation of bone mass is increasingly an issue. GnRH analogues are currently recommended (UK licensing guidelines) for a maximum of six months' treatment because of detrimental affects on bone mineralization 3 , although there are data to suggest that further courses of treatment may have little further longterm detrimental effect on bone density 4 and that concomitant administration of norethisterone may negate this effect 5 . Side-effects include menopause-like symptoms such as¯ushing, vaginal dryness and reduction in breast size 6 .
Both our patients were greatly relieved by treatment with nafarelin, and each withdrawal of the treatment led almost immediately to an attack of AIP (with hospital admission in patient 1). Both are keen to continue treatment. The potential drawback of this highly effective treatment is osteoporosis secondary to oestrogen de®ciency. Low-dose oestrogen replacement therapy, by either the oral or the transdermal route, precipitated AIP attacks in patient 1 but other bone-conserving therapies such as bone-speci®c oestrogens or bisphosphonates remain an option. Papillary cystic epithelial neoplasms of the pancreas (PCENP) are rare tumours that appear in women in the second or third decade of life. They are easily mistaken for more sinister neoplasms.
Pancreatic tumour with jaundice: good prognosis

CASE HISTORY
A high-school girl, aged 15, was admitted for evaluation of a cholestatic syndrome (direct bilirubin 128 mmol/L, alkaline phosphatase 640 U/L, alanine aminotransferase 60 U/L). Nothing abnormal was found on abdominal examination but a computed tomographic (CT) scan revealed a well circumscribed mass, 5 cm in longest diameter, in the head of the pancreas, partly cystic and partly solid (Figure 1) .
At laparotomy the tumour was found to have a capsule and to be displacing rather than in®ltrating the adjacent tissues. The common bile duct (CBD) was distended. The tumour was mobilized from the adjacent duodenum and inferior vena cava and enucleated without dif®culty from 
